| EMA number | EMEA/H/C/005413 |
| ATC code | L01EX23 |
| Authorisation | 18 November 2021 |
| Withdrawn | 24 October 2024 |
| Revision | 8 |
Gavreto is indicated as monotherapy for the treatment of adult patients with rearranged during transfection (RET) fusion-positive advanced non-small cell lung cancer (NSCLC) not previously treated with a RET inhibitor.